← FDA DRUG APPROVALS

FDA ANDA · ANDA202468

MONTELUKAST SODIUM

Sponsor: AUROBINDO PHARMA LTD

APPLICATION
ANDA202468
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-03
LATEST ACTION
2022-01-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

MONTELUKAST SODIUMPrescription
MONTELUKAST SODIUM EQ 10MG BASE · TABLET · ORAL

Approval history

2022-01-19Labeling · Supplement 27 · standardAP
2020-08-14Labeling · Supplement 24 · standardAP
2019-11-05Labeling · Supplement 20 · standardAP
2019-11-05Labeling · Supplement 23 · standardAP
2018-07-23Labeling · Supplement 16 · standardAP
2015-12-08Labeling · Supplement 14 · standardAP
2015-12-08Labeling · Supplement 11 · standardAP
2013-06-04Labeling · Supplement 7 · standardAP
2012-12-13Labeling · Supplement 4 · standardAP
2012-12-13Labeling · Supplement 2 · standardAP
2012-08-03UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →